Shows
Oncology On The GoWhat Were the Key Abstracts and Presentations at The 2026 Tandem Meetings?
At the 2026 Tandem Meetings, CancerNetwork® spoke with a variety of experts who presented on key developments and advancements across hematologic oncology. As part of different oral presentations and poster sessions, researchers and clinicians shared updated findings that may influence the management of myelodysplastic syndromes (MDS), leukemia, lymphoma, and other blood cancer types.First, Fernando Duarte, head of the Bone Marrow Transplant Service at Walter Cantídio University Hospital (HUWC), hematologist and professor at the Federal University of Ceará, and president of the Brazilian Society of Cell Therapy and Bone Marrow Transplant, highlighted his presentation analyzing trends associated wit...
2026-02-1611 min
ER/ICU RadioCAR-T細胞療法に伴う主要な有害事象Major Adverse Events With Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and ResuscitationAnn Emerg Med. 2026;87:229-238.キメラ抗原受容体T細胞（CAR-T）療法は、白血病やリンパ腫などの血液がん治療において革新的な進歩をもたらしたが、従来の化学療法とは異なる独自の副作用を引き起こす。主な合併症には、サイトカイン放出症候群（CRS）、免疫エフェクター細胞関連神経毒性症候群（ICANS）、および免疫エフェクター細胞関連血球貪食性リンパ組織球症様症候群（IEC-HS）がある。CRSは最も頻度の高い副作用であり、発熱、低血圧、低酸素症を特徴とする。重症度は米国移植細胞治療学会（ASTCT）の基準によって格付けされ、治療にはIL-6受容体拮抗薬であるトシリズマブやステロイドが用いられる。ICANSは認知機能の低下、失語症、震え、痙攣、脳浮腫などの神経症状を呈し、成人ではICEスコア、小児ではCAPDスコアを用いて評価される。IEC-HSは稀ではあるが致死率が高い過剰炎症状態で、CRSの解熱後や改善後に出現することがある。近年、CAR-T療法が外来で行われるケースが増加しており、救急診療科（ED）の医師がこれらの合併症の初期対応を行う機会が増えている。救急現場では、これらの副作用を敗血症や髄膜炎などの他の致命的な疾患と迅速に鑑別し、適切な蘇生処置と専門医へのコンタクトを行うことが求められる。内的妥当性本論文は、既存の主要な臨床試験（ELIANA、JULIET、ZUMA-1など）のデータや、ASTCTなどの国際的なコンセンサスガイドラインに基づいて構成された臨床レビューである。個別の新規介入を検証する研究デザインではないため、エビデンスの統合という点では信頼性が高い。ただし、レビューという性質上、ソースとなる各試験のバイアスリスク（非盲検試験や単群試験が多い点など）をそのまま引き継いでいる側面がある。外的妥当性成人および小児の両方の患者層を対象としており、かつ現在の臨床現場で標準的に使用されているCAR-T製品を網羅しているため、救急医療現場における汎用性は非常に高い。特に、外来管理への移行という最新のトレンドを反映しており、専門施設以外の医師にとっても実用的な指針となっている。一方で、本論文で推奨されている診断法や薬剤（トシリズマブなど）の利用可能性は、医療機関の設備や地域のリソースに依存する可能性がある。
2026-02-0311 min
ASTCT TalksBest Practice Considerations for Infection Prevention and Management Post-CAR TIn this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD(The University of Texas MD Anderson Cancer Center; Pharmacy SIG Immediate Past-Chair), sits down with Zainab Shahid, MD (Memorial Sloan Kettering Cancer Center; ID SIG Chair), and Gabriela Maron, MD (St. Jude Children’s ResearchHospital). As coauthors of the ASTCT Practice Guidelines, "American Society for Transplantation and Cellular Therapy Best Practice Considerations for the Prevention and Management of Infections After Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies," recently published in Transplantation and Cellular Therapy, they discuss the implementation of critical strategies for safeguarding CAR T recipients....
2026-01-1336 minASTCT TalksLIVE From ASH: Multiple Myeloma Treatment Redefined by Bispecific Antibodies and T-Cell TherapiesIn a special cobranded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, a physician-researcher who specializes in multiple myeloma at Fred Hutchinson Cancer Center, and Brooke Adams, PharmD, BCOP, a clinical pharmacist and transplant specialist at Orlando Health, break down practice‑changing data in multiple myeloma from the ASH Annual Meeting.The experts focus on bispecific antibodies and BCMA CAR T-cell therapies and close the discussion by reflecting on how data is redefining the treatment paradigm in multiple myeloma, raising possibilities of deep MRD...
2026-01-0627 min
Oncology On The GoWhat’s New in Hematology/Oncology? Discussing the 2025 ASH Annual MeetingAfter the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT) to highlight these potential changes.Adams and Banerjee discussed abstracts from the meeting, including the phase 3 MajesTEC-3 trial (NCT05083169), which evaluated teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) in patients with relapsed/refractory mu...
2025-12-2928 minASTCT TalksWhat Clinicians Need to Know About Chronic GVHD and ImmunityIn this episode of ASTCT Talks, supported by an educational grant from Sanofi US, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, sits down with Dr. Sanjeet Singh Dadwal, MD, chief of infectious diseases at City of Hope, to explore a critical aspect of chronic graft-versus-host disease (GVHD): immune dysfunction and infection risk.The discussion highlights:• How chronic GVHD independently contributes to immune deficits and infection susceptibility.• Infectious risks associated with FDA-approved therapies for chronic GVHD.• Common infections in this population and why vigilance matters.• Practical guidance on prophyla...
2025-12-1620 minASTCT TalksPulmonary Manifestations of Chronic GVHDIn this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler, from Dana-Farber Cancer Institute, and Dr. Guang-Shing Cheng, from the University of Washington and Fred Hutchinson Cancer Center, discuss how to identify and manage non-infectious lung complications following allogeneic transplant. From differentiating infection versus inflammation to managing conditions like organizing pneumonia (OP), this conversation offers practical insights for clinicians.For a deeper dive, explore Dr. Cheng’s many publications on pulmonary topics in the Journal of Transplantation and Cellular Therapy. Additionally, read the article “Late-Onset Noninfectious Pulmonary Comp...
2025-12-1623 minASTCT TalksTackling Cognitive Challenges in Survivorship CareIn this episode of ASTCT Talks, host Christina Ferraro, nurse practitioner from the Cleveland Clinic, sits down with Vanessa Kennedy, MD, from Stanford University, to address a critical aspect of survivorship: cognitive health, including issues like brain fog, memory lapses and reduced executive function.The discussion highlights:New ASTCT consensus guidelines on cognitive assessment.Practical strategies for operationalizing cognitive screening in busy clinical settings. How factors like anxiety, depression, sleep and polypharmacy influence cognition — and why addressing these is critical. Emerging interventions, from cognitive rehabilitation to surprisingly effective options like jigsaw puzzles.This episode offers ac...
2025-12-0224 minASTCT TalksTitans of Transplant: Innovations in CAR T Cell TherapyIn this episode of ASTCT’s Titans of Transplant series, Dr. Taha Al-Juhaishi welcomes Dr. Sattva Neelapu of MD Anderson Cancer Center for a deep and insightful conversation on the evolution, challenges and future of CAR T therapy.From the groundbreaking ZUMA-1 trial to today’s expandinglandscape of commercial CAR T products, Dr. Neelapu shares pivotal clinical experiences, lessons learned in toxicity management and reflections on mentorship and innovation. This episode offers a look at the progress made, the barriers that remain and the opportunities ahead for the next generation of leaders in cellular therapy.
2025-10-2441 minASTCT TalksPharmacist Takeover: BCMA Bispecifics and CAR T-Cell TherapyIn this episode of ASTCT Talks, we're excited to share a special feature from the Pharmacy Focus: Oncology Edition podcast in honor of American Pharmacists Month, featuring members of ASTCT Pharmacy SIG. Expert pharmacists share key insights on BCMA bispecifics, CAR T-cell therapies, and other cellular treatments for multiple myeloma. Moderated by Ryan Shaw, PharmD, of the University of North Carolina at Chapel Hill, the discussion features Sara Ann Scott, PharmD, of Emory Winship Cancer Institute, and Kelley Julian, PharmD, of the University of Utah Huntsman Cancer Institute. Together, they explore treatment sequencing strategies for cellular therapies...
2025-10-1637 minASTCT TalksOptimizing Care for TILs, Cellular Therapy in Melanoma and Solid TumorsA panel of oncology pharmacists discusses the role oflifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors. Featuring Brooke Adams, PharmD, BCOP Natalie Brumwell, PharmD, BCOP Bryant A. Clemons, PharmD, BCOP In a special co-branded episode between Oncology On theGo, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. Th...
2025-10-0926 min
Oncology On The GoOptimizing Care for TILs, Cellular Therapy in Melanoma and Solid TumorsIn a special co-branded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New Yor...
2025-10-0626 minASTCT TalksCord Blood Transplantation: Past, Present and Future InnovationsIn this episode of ASTCT Talks, Dr. Taha Al-Juhaishi is joined by Dr. Filippo Milano, director of the Cord Blood Transplant Program at Fred Hutch, for a wide-ranging conversation on the evolving role of umbilical cord blood transplantation. From its historical milestones to emerging clinical strategies, Dr. Milano shares insights drawn from decades of research, practice and mentorship. The discussion explores the unique biological advantages of cord blood, including its potent graft-versus-leukemia effect and low incidence of chronic GVHD. Dr. Milano outlines ideal patient profiles, unit selection criteria and conditioning regimens, while addressing challenges like engraftment delays a...
2025-10-0233 min
HemeTalks: Conversations in Hematology EducationBridging the Gap: Coordinating CAR-T Care Between Community and Academic PracticesJoin Drs. Caimi and Sdrimas for a focused discussion on the coordination of CAR-T therapy between academic and community practices. As CAR-T use expands, ensuring seamless communication and shared responsibilities between care teams is essential. Using a real-world patient case, this episode explores how to navigate logistics, manage toxicities, and support patients in both settings—delivering collaborative, high-quality care. Learning Objectives:1. Understand the shared roles and responsibilities in CAR-T patient management across care settings 2. Identify communication strategies that support safe and effective care coordination 3. Explore real-world barriers and solutions to br...
2025-09-1820 minASTCT TalksManaging Mental Health in Chronic GVHDIn this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler is joined by psychiatrist and physician-scientist Dr. Hermioni Amonoo to explore the psychological complexities faced by patients undergoing stem cell transplantation and living with chronic GVHD. Drawing from her research and clinical experience, Dr. Amonoo introduces a biobehavioral framework that integrates biological, psychological and social factors.This episode offers practical insights and compassionate strategies for improving psychological well-being in transplant patients, highlighting the importance of interdisciplinary care.For more information, read the article “A Biobehavioral Perspective on Caring for All...
2025-09-1230 minASTCT TalksPhysician-Patient Communication in the Post-Transplant SettingIn this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler sits down with Dr. Ana Barata to discuss the critical role of physician-patient communication in GVHD and stem cell transplantation. Together, they unpack the complex emotional and psychological landscape facing transplant survivors and the communication barriers that often go unspoken. Dr. Barata shares insights into the challenges faced by both patients and providers, ranging from unspoken anxiety and cognitive dysfunction to hesitations around discussing complementary therapies. This episode offers a look at how better communication can transform th...
2025-08-0527 minASTCT TalksDelayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To KnowIn this episode of ASTCT Talks, Dr. Rahul Banerjee sits down with Dr. Kenneth Lim and Dr. Yi Lin of Mayo Clinic to discuss a critical and emerging topic in CAR T-cell therapy: delayed neurotoxicities following cilta-cel treatment in multiple myeloma. They break down the clinical features of nerve palsies and Parkinsonism-like symptoms, share diagnostic and treatment strategies and explore emerging predictive markers like absolute lymphocyte count. Given that cilta-cel is increasingly being used in second-line myeloma treatment and is even being studied in first-line treatment to replace stem cell transplantation, this conversation is a timely and insightful look at imp...
2025-07-1721 minASTCT TalksTitans of Transplant: Dr. Daniel WeisdorfIn the next installment of ASTCT's Titans of Transplant series, Dr. Shernan Holtan sits down with Dr. Daniel Weisdorf—renowned leader, mentor and pioneer in cellular therapy and transplantation—for a reflective and engaging conversation on the evolution of the field. From the early days of sibling-only donors and bone marrow harvests to today’s innovations in GVHD prophylaxis and cord blood transplantation, Dr. Weisdorf shares personal anecdotes, pivotal clinical insights and lessons in mentorship, writing and research. Together, they explore the milestones, challenges and future directions in transplant and cellular therapy—offering a powerful...
2025-06-251h 06ASTCT TalksCAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.Banerjee is an assistant professor i...
2025-06-1735 minOncology On The GoCAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the H...
2025-06-0935 minASTCT TalksHomegrown CAR-T: Expanding Access Through Academic InnovationIn this episode of ASTCT Talks, Dr. Taha Al-Juhaishi welcomes Dr. Marcos de Lima, hematologist-oncologist at The Ohio State University Comprehensive Cancer Center, to explore the rapidly evolving field of homegrown CAR-T therapies. Together, they dive into the definitions, motivations and barriers of decentralized CAR-T manufacturing, the global innovation landscape and what it takes to build sustainable academic cell therapy programs. Dr. de Lima shares his firsthand experience launching point-of-care CAR-T programs, the regulatory and payer landscape and the future of academic-industry collaboration in expanding access. It’s a must-listen for anyone interested in the future of decentralized cell th...
2025-06-0443 minASTCT TalksHomegrown CAR-T: Expanding Access Through Academic InnovationIn this episode of ASTCT Talks, Dr. Taha Al-Juhaishi welcomes Dr. Marcos de Lima, hematologist-oncologist at The OhioState University Comprehensive Cancer Center, to explore the rapidly evolving field of homegrown CAR-T therapies. Together, they dive into the definitions, motivations and barriers of decentralized CAR-T manufacturing, the globalinnovation landscape and what it takes to build sustainable academic cell therapy programs. Dr. de Lima shares his firsthand experience launching point-of-care CAR-T programs, the regulatory and payer landscape and the future of academic-industry collaboration in expanding access. It’s a must-listen for anyone interested in the future of decentralized cell therapy and in...
2025-06-0443 minASTCT TalksRethinking Tacrolimus Targets in the PTCy EraIn this episode of ASTCT Talks, Dr. Shernan Holtan welcomes Andrew Lin, Manager of Clinical Pharmacy Services of Adult BMT and CTS at Memorial Sloan Kettering Cancer Center, to discuss the evolving role of tacrolimus levels in GVHD prophylaxis within the post-transplant cyclophosphamide (PTCy) era. They explore findings from a recent retrospective study examining whether higher tacrolimus levels offer added protection against GVHD, what this means for toxicity and patient outcomes and how these insights are shaping dosing strategies. The conversation also looks ahead to future research areas, including MMF optimization and the potential for simplified, patient-centered prophylaxis regimens.
2025-05-1913 minASTCT TalksReviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-ThalassemiaIn a special co-branded episode between Oncology On theGo hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Nora M. Gibson, MD, MSCE, and Taha Al-Juhaishi, MD, spoke about real-world applications of betibeglogene autotemcel (beti-cel; Zynteglo) as a treatment for patients with beta (β)-thalassemia.They spoke in the context of a study that Gibson presented at the 2025 Tandem Meetings, which evaluated patients who received commercial beti-cel in a single-center cohort following the agent’s FDA approval in August 2022. ¹ ²Nora is a fourth-year fellow in bone marrow transplant andcellular therapy at the C...
2025-05-0524 minOncology On The GoReviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-ThalassemiaIn a special co-branded episode between Oncology On the Go hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Nora M. Gibson, MD, MSCE, and Taha Al-Juhaishi, MD, spoke about real-world applications of betibeglogene autotemcel (beti-cel; Zynteglo) as a treatment for patients with beta (β)-thalassemia. They spoke in the context of a study that Gibson presented at the 2025 Tandem Meetings, which evaluated patients who received commercial beti-cel in a single-center cohort following the agent’s FDA approval in August 2022.
Nora is a fourth-year fellow in bone marrow transplant and cellular therap...
2025-05-0524 minASTCT TalksKey CAR T and Transplantation Presentations From The 2025 Tandem MeetingCancerNetwork®, in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT)®, hosted a Twitter/X Space during the 2025 Tandem Meetings. The live conversation featured Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, and Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center. Together, they shared expert commentary on new data in CAR T-cell therapy and hematopoietic cell transplantation.With insights drawn from posters, oral abstracts, and late-breaking presentations, the session unpacked both clinical takeaways and implications for patient care.Highlights included:LBA1 – Ide-cel + lenalidomide maintenance post-transplant in MM patients“This m...
2025-04-2456 minASTCT TalksUnderstanding Cutaneous GVHD: Clinical Insights and Care StrategiesWelcome to the fourth episode of ASTCT Talks’ exclusive 8-part series, supported by an educational grant from Sanofi US. In this episode, former ASTCT President Dr. Corey Cutler sits down with Dr. Connie R. Shi from the Cutaneous Oncology Program at Dana-Farber Cancer Institute. They discuss Dr. Shi's recent article, Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.Tune in as they explore the complexities of cutaneous GVHD, including acute and chronic presentations, diagnostic challenges and skin-directed treatment strategies such as topical steroids and phototherapy. They also cover key considerations for recognizing and diagnosing cu...
2025-04-1826 minOncology On The GoKey CAR T and Transplantation Presentations From The 2025 Tandem MeetingCancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center. The conversation took place during the 2025 Tandem Meeting and highlighted many significant presentations and posters on CAR T-cell therapies and transplantation, Banerjee’s and Holtan’s respective areas of expertise.The following trials were discussed:LBA1 - Phas...
2025-03-0356 minASTCT TalksThe Role of Lifestyle Medicine in Chronic GVHD with Dr. Steven PavleticWelcome to the third episode of ASTCT Talks’ exclusive 8-part series, supported by an educational grant from Sanofi US. In this series, ASTCT President Dr. Corey Cutler sits down with authors from the latest Graft-versus-Host Disease and Late Effects Following Allogeneic Transplantation journal collection to discuss their research and its implications for patient care.In this episode, Dr. Cutler is joined by Dr. Steven Z. Pavletic, the GVHD and Late Effects Section and Myeloid Malignancies Program Director at the NIH in Bethesda, Maryland. Widely recognized as a titan in chronic GVHD research, Dr. Pavletic explores an emerging ye...
2025-02-1325 minASTCT TalksOptimizing Graft Selection: A New Era in Transplantation with Dr. Lori MufflyIn this episode of ASTCT Talks, Dr. Taha Al-Juhaishi welcomes Dr. Lori Muffly, Associate Professor in the Division of Blood and Marrow Transplantation-Cellular Therapies at Stanford University, to discuss groundbreaking advancements in graft selection and manipulation in hematopoietic cell transplantation. They explore the evolution of graft engineering strategies aimed at improving patient outcomes, with a focus on Orca-T, an innovative cell therapy designed to reduce graft-versus-host disease while maintaining graft-versus-leukemia effects. Dr. Muffly provides insights into the clinical development of this promising therapy, its impact on patient recovery, and the future of transplantation. Tune in to learn about the...
2025-01-2339 minASTCT TalksOral Chronic Graft-Versus-Host Disease and Oral Health After Allogeneic Hematopoietic Cell Transplantation — What the Care Team Needs To KnowWelcome to the second installment of an exclusive 8-part ASTCT Talks series, supported by an educational grant from Sanofi US. In this series, ASTCT President Dr. Corey Cutler speaks with authors from each article in the latest
Graft versus Host Disease and Late Effects Following Allogeneic Transplantation Journal collection.
In this episode, Dr. Cutler is joined by Dr. Nathaniel S. Treister, a recognized expert in oral medicine, to discuss the intricacies of oral chronic GVHD and its impact on oral health following allogeneic hematopoietic cell transplantation. They explore the diagnostic criteria, effective management strategies, and long-term care...
2024-12-1122 minASTCT TalksTitans of Transplant: Dr. Renier BrentjensIn the next episode of ASTCT's "Titans of Transplant," Dr. Shernan Holtan hosts Dr. Renier Brentjens, a pioneer in CAR T-cell therapy and a transformative leader in transplantation and cellular therapy. Dr. Brentjens discusses the challenges and breakthroughs behind developing the first chimeric antigen receptors (CARs), the pivotal discovery of CD19-targeting hybridomas, and the determination needed to turn bold ideas into clinical reality. Tune in for an insightful look at how early experiments paved the way for today’s CAR T-cell advancements, capturing the passion, persistence, and pivotal moments that shaped a new era in cancer treatment.
2024-11-121h 07ASTCT TalksUnderstanding Ocular Graft-versus-Host Disease to Facilitate an Integrated Multidisciplinary ApproachWelcome to the first installment of an exclusive 8-part ASTCT Talks series, supported by an educational grant from Sanofi US. In this series, ASTCT President Dr. Corey Cutler speaks with authors from each article in the latest ASTCT Journal of Transplantation and Cellular Therapy GVHD supplement.
In this opening episode, Dr. Cutler is joined by Dr. Katie Luo, a leading ophthalmologist, to discuss the complexities of ocular GVHD, why it goes beyond “just dry eye,” and how an integrated, multidisciplinary approach can offer better patient outcomes.
For further insights, read Dr. Luo’s full article, “Understa...
2024-10-2922 minASTCT TalksLeveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic DiseasesIn a special co-branded episode between Oncology On the Go hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Alexis K. Kuhn, PharmD, BCOP, spoke with Katie Bruce, PharmD, BCPPS, and Susie Long, PharmD, about the use of approved cell-based gene therapies for patients with sickle cell disease, beta thalassemia, adrenoleukodystrophy (ALD), and metachromatic leukodystrophy (MLD). These panelists shared the pharmacist’s perspective on ensuring quality care with these ex vivo gene therapies across all treatment phases, including mobilization, conditioning, and infection prophylaxis.
Kuhn is an ambulatory Pedia...
2024-10-2247 min
Oncology On The GoLeveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic DiseasesIn a special co-branded episode between Oncology On the Go hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Alexis K. Kuhn, PharmD, BCOP, spoke with Katie Bruce, PharmD, BCPPS, and Susie Long, PharmD, about the use of approved cell-based gene therapies for patients with sickle cell disease, beta thalassemia, adrenoleukodystrophy (ALD), and metachromatic leukodystrophy (MLD). These panelists shared the pharmacist’s perspective on ensuring quality care with these ex vivo gene therapies across all treatment phases, including mobilization, conditioning, and infection prophylaxis.
Kuhn is an ambulatory Pediatric Hematology/Oncology/BMT P...
2024-10-2147 minASTCT TalksOutpatient CAR T: Navigating Logistics and Patient CareThis episode of ASTCT Talks dives into outpatient CAR T therapy, exploring logistics, challenges, and success strategies. Host Dr. Zahra Mahmoudjafari leads a panel of experts to share insights from their innovative programs.
The panel features Robb Richards, Administrative Director of Cell Therapy and Transplant at Penn Medicine; Dr. Katie Gatwood, Clinical Pharmacy Specialist at Vanderbilt University Medical Center; and Dr. Taha Al-Juhaishi, Associate Director at the University of Oklahoma’s Transplant and Cell Therapy Program. Topics include outpatient program structures, toxicity management, and the evolving role of cell therapies beyond hematologic malignancies.
...
2024-10-1437 minASTCT TalksBridging the Gap: Addressing Disparities in GVHD CareIn this episode of ASTCT Talks, host Dr. Andrés Gómez De León is joined by Dr. Nandita Khera and Dr. Alexandra Gomez Arteaga to explore the critical issue of disparities and barriers to care in graft-versus-host disease (GVHD). The discussion delves into the factors contributing to unequal access to hematopoietic cell transplantation, such as socioeconomic status, race, and ethnicity, both in the U.S. and globally. The guests highlight initiatives like the ACCESS Initiative by ASTCT and the National Marrow Donor Program, aimed at addressing these disparities through advocacy, awareness, and training for junior faculty. They als...
2024-09-2542 minASTCT TalksManaging Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma SubgroupsIn a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy.
Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Cente...
2024-09-0318 min
Oncology On The GoManaging Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma SubgroupsIn a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy.Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and a professor of...
2024-09-0218 minASTCT TalksExploring Insights From CAR-TITUDE 4 and KarMMa-3 Trials with Dr. Jens HillengassIn this episode of ASTCT Talks, Dr. Muhammad Salman Faisal is joined by Dr. Jens Hillengass. Dr. Hillengass discusses the latest advancements in CAR T cell therapy, focusing on its application in early-line settings following the results of the CAR-TITUDE 4 and KarMMa-3 trials. Tune in as he shares insights on the efficacy, patient selection and future directions of CAR-T cell therapy in multiple myeloma. This episode is supported by Johnson & Johnson and Legend Biotech. Don’t miss out on this informative discussion with one of the leading experts in the field.
About Dr. Jens Hillengass
Je...
2024-07-2024 minASTCT TalksA New Era in GVHD Prophylaxis: A Conversation With Dr. Samer Al-HomsiIn this episode of "ASTCT Talks," Dr. Shernan Holtan sits down with Dr. Samer Al-Homsi, as he shares his insights on the future of graft versus host disease (GVHD) prophylaxis, particularly in haploidentical transplantation.
Dr. Al-Homsi delves into the innovative CAST regimen, which combines post-transplant cyclophosphamide, abatacept and short-duration tacrolimus. Learn about the challenges, breakthroughs and promising results that could revolutionize how we approach GVHD prevention and treatment, making a future without GVHD a reality.
Listen in as we explore the potential for reducing transplant toxicities and the impact on patient care.
About...
2024-06-2529 minASTCT TalksBeyond Remission: Navigating the Late Effects of Pediatric CAR T-Cell TherapyIn this episode "ASTCT Talks,” hosts Rebecca Epperly, MD, and Aimee Talleur, MD, from St. Jude Children's Research Hospital, dive into the pioneering realm of CAR T-cell therapy and its late effects on pediatric patients. The discussion unfolds at the intersection of innovation and caution, highlighting the recent sessions from the 2024 Tandem meetings. They explore the emerging challenges and lack of data concerning long-term impacts of this revolutionary treatment, particularly in pediatric, adolescent, and young adult populations. This episode sheds light on both the immense potential and the imperative need for comprehensive studies to better understand and mitigate the lo...
2024-04-2924 minASTCT TalksA Conversation with Mike Niles: Author of ‘Hard Graft: Our Fight Against Killer Blood’In this latest episode of ASTCT Talks, Rachel Schollmeier and NMDP’s Samantha Watters host author Mike Niles, delving into the captivating history of the Anthony Nolan bone marrow transplant register. Explore the evolution of transplantation, from no donor registries to international initiatives, and gain a deeper understanding of the challenges faced by bone marrow registries today. Discover the inspiring narratives behind bone marrow donation and the transformative advancements that continue to shape the future of transplantation. Plus, don't miss the chance to connect with Samantha's podcast, NMDP ‘Explore Cell Therapy,' for even more insights into the world of c...
2024-02-1241 minASTCT TalksTitans of Transplant: Dr. Stephanie LeeIn the next installment of ASTCT’s Titans of Transplant series, Dr. Stephanie Lee is interviewed by Dr. Jennifer Saultz.
Dr. Lee shares her journey from Seattle to becoming a professor at Fred Hutch Cancer Center. The conversation highlights early motivations, challenges faced during fellowship, and the influence of her father's advice to always strive for the best. They also discuss Dr. Lee's groundbreaking work in chronic graft-versus-host-disease research, collaborative efforts, FDA-approved treatments, and the evolving landscape in the field.
The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nu...
2024-01-1618 minASTCT TalksExploring the BMT CTN 1703 StudyIn this latest episode of ASTCT Talks, Dr. Andrés Gómez De León sits down with Dr. Javier Bolaños-Meade. They delve into the groundbreaking BMT CTN 1703 study.
Together, they explore the historical context of GVHD prophylaxis, the evolution of post-transplant cyclophosphamide (PTCy), and the essential contributions of the BMT CTN in transplantation research. Dr. Bolaños-Meade provides key insights into the study's design, conditioning regimens, and cell doses. The episode unravels the intricacies of PTCy, addressing both its merits and potential drawbacks, including Grade 2 infections, CMV reactivation, and cardiotoxicity, offering an exploration of the trans...
2023-12-0454 minASTCT TalksNavigating CAR-T SurvivorshipIn this latest episode of ASTCT Talks, Cory M. Edgar, DMSc, PA-C, sits down with Sarah Fitzmaurice, APRN, where they delve into the evolving landscape of survivorship care, particularly in the realm of CAR T-cell therapy. They discuss the development of CAR T-specific protocols, emphasizing the importance of post-treatment monitoring and patient education. They also explore the challenges of defining survivorship, the multidisciplinary nature of care, and insights into late effects, deconditioning, cognitive changes, and psychological concerns beyond the first year.
Tune into this episode of ASTCT Talks for a deep dive into the...
2023-11-2840 minASTCT TalksBeyond BCMA: Exploring Talquetamab in Myeloma TherapyIn this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Amrita Krishnan, MD. They delve into the use of GPRC5D as a target in myeloma therapy, specifically focusing on Talquetamab.
Dr. Krishnan shares insights from the MonumenTAL-1 trial, discussing the dosing schedules and response rates with GPRC5D-targeted therapy. They explore the unique toxicities associated with this treatment, such as cytokine release syndrome and skin and nail toxicities. The conversation also touches on the considerations for patients who have previously received BCMA-targeted therapies and the potential of...
2023-11-1517 minASTCT TalksBehind the Scenes of CAR-T Therapy at University of California, DavisIn this latest episode of ASTCT Talks, Misty Evans, DNP, APRN, CPNP-AC, sits down with Flora Stondell, FNP, to delve into the intricacies of University of California, Davis’ (UC Davis’) transplant and cellular therapy program, with a specific focus on CAR T cell therapy.
In this insightful conversation, they discuss topics such as patient access, the timeline from referral to CAR-T therapy initiation, overcoming insurance barriers, and the patient education process. Stondell shares valuable insights gained from her experience in the field, highlighting the crucial role of advanced practice providers (APPs) in delivering high-quality care...
2023-11-0129 minASTCT TalksRevitalizar, Prosperar y Sobrevivir: El Poder del Movimiento en la Recuperación de los TrasplantesEn este último episodio de ASTCT Talks, el Mensaje del Presidente de octubre, el Dr. Andrés Gómez De León está acompañado por el Dr. Miguel Perales, Presidente de ASTCT y Jefe del Servicio de Trasplante de Médula Ósea en Adultos del Memorial Sloan Kettering Cancer Center y Profesor de Medicina en Facultad de Medicina Weill Cornell. Profundizan en el papel vital, pero a menudo pasado por alto, de la actividad física en los trasplantes de terapia celular y hematopoyética, discutiendo desafíos, enfoques proactivos como la "prehabitación", la brecha en la investigació...
2023-10-1623 minASTCT TalksRevitalize, Thrive, and Survive: The Power of Movement in Transplant RecoveryIn this latest episode of ASTCT Talks, the October President's Message, Dr. Andrés Gómez De León is joined by Dr. Miguel Perales, President of ASTCT and Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College. They delve into the vital but often overlooked role of physical activity in hematopoietic and cell therapy transplants, discussing challenges, proactive approaches like "pre-hab," the research gap, and the transformative effects of movement on recovery.
Click here to listen to this episode in...
2023-10-1618 minASTCT TalksA PTCy of Relief: GVHD Prophylaxis in Matched Unrelated DonorsIn this latest episode of ASTCT Talks, Dr. Rebecca Gonzalez sits down with Dr. Katie Gatwood and Dr. Timothy Porter to kick off National Pharmacy Month by discussing the clinical implications of post-transplant cyclophosphamide (PTCy) use outside of the haploidentical setting. They delve into their respective cancer centers' primary donor sources for match unrelated donors and the breakdown of conditioning intensity within their hematologic patients. They delve into the future of PTCy discussing the potential for earlier de-escalation of immunosuppressants to limit drug-related toxicities and optimize patient outcomes as well as important supportive care considerations. Despite the exciting prospects...
2023-10-1245 minASTCT TalksNavigating Intersectionality in GVHD and Transplant MedicineIn this latest episode of ASTCT Talks, we sit down with Associate Professor Nada Hamad, senior staff specialist in bone marrow transplant, and a clinical and laboratory hematologist at St. Vincent’s hospital in Sydney, to explore the impact of intersectionality on graft-versus-host disease (GVHD) in transplant recipients. She dives into how gender and race can compound biases in research, education, and clinical practice, affecting GVHD severity and outcomes. Further discussions center on the need for research into how age, socioeconomic status, and geographic region intersect with GVHD incidence and treatment strategies. In addition, Nada stresses the need to in...
2023-09-2839 minASTCT TalksAdvancing ALL Treatment and Insights on MRD MonitoringIn this latest episode of ASTCT Talks, Christina Cho, MD, interviews Lori Muffly, MD, MS. During the conversation, Dr. Muffly emphasizes the need for more randomized data in ALL treatment and addresses the unique challenges of treating young adults, including fertility preservation. Dr. Muffly also emphasizes the significance of measurable residual disease (MRD) monitoring using the clonoSEQ® Assay, offering valuable insights into leukemia care.
About Lori Muffly, MD, MS
Lori Muffly, MD, MS, an Associate Professor of Medicine at Stanford University, specializes in adult acute leukemia research, clinical trials, and hematopoietic cell transplantation. Her work f...
2023-09-1839 minASTCT TalksMonitoring After CAR-T Therapy for Multiple Myeloma: The APP PerspectiveIn this latest episode of ASTCT Talks, Rahul Banerjee interviews Josh Epworth, a lead nurse practitioner in the plasma cell disorders clinic at the Fred Hutchinson Cancer Center. They delve into the topic of monitoring after CAR-T therapy for multiple myeloma. Mr. Epworth shares insights from his experience in the outpatient setting, discussing issues like hypogammaglobulinemia, immune cell functionality, and infections that may arise after CAR-T treatment. They also touch on monitoring for cytomegalovirus (CMV) and other respiratory viruses, as well as the importance of developing close relationships with local healthcare providers to ensure patients receive timely care.
2023-08-1825 min
Cancer Care ConnectionsCAR T-Cell Therapy: Engineering the Immune System to Fight CancerOn this week’s episode of Cancer Care Connections, Cheryl Tan spoke with Dr. Gary Simmons. Dr. Simmons is a hematologist oncologist and part of the transplant and cellular therapy team for Virginia Oncology Associates. Cheryl and Dr. Simmons dove into CAR T-cell therapy, how it is a revolutionary treatment for fighting blood cancer, and how continued research of CAR T could change the landscape of cancer treatment.If you haven't already, consider listening to episode 2, Introduction to Blood Cancer with Dr. Jared Kobulnicky. He presented a high-level overview of what blood cancer is and the latest dev...
2023-08-0925 minASTCT TalksTitans of Transplant: Dr. Rick JonesIn this latest episode of ASTCT Talks, Dr. Tania Jain engages in a conversation with Dr. Richard Jones, the BMT director and co-director of the Hematologic Malignancies Programs at Johns Hopkins University. He shares his journey in the field of oncology and transplantation, reflecting on the life events and experiences that led him to this path. He delves into the groundbreaking development of post-transplant cyclophosphamide (PTCy) and its significant impact on transplant procedures. Gain insights into the behind-the-scenes efforts and the role PTCy has played in expanding donor options and improving graft-versus-host disease prophylaxis. The episode also highlights Dr...
2023-07-1727 min
Blood Cancer TalksEpisode 25. Managing Acute Toxicities of CAR T-cell TherapyIn this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.Here are some of the key articles we discussed:1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score: https://pubmed.ncbi.nlm.nih.gov/34166502/ 3. “How I treat cytopenias after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36800563/ 4. Immune Effector Cell-Associated HLH-L...
2023-06-2849 minASTCT TalksBreaking Barriers and Dispelling Misconceptions in TransplantationIn this latest episode of ASTCT Talks, the June President's Message, we are joined by Dr. Miguel Perales, President of ASTCT and Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College. This episode features a personal story of a patient with aggressive lymphoma who initially had doubts about the effectiveness of transplantation but ultimately experienced a fulfilling life post-transplant. Dr. Perales' story underscores the significance of educating colleagues about improved outcomes and advancements in cell therapies. He also delves into the primary barriers to access...
2023-06-2013 minASTCT TalksHow to Handle CAR-T Waitlists in Multiple MyelomaIn this latest episode of ASTCT Talks, Christina Ferraro, MSN, APRN-CNP, BMTCN, is joined by Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, to discuss criteria used to determine who is eligible for CAR-T cells, efforts between multi-disciplinary teams to select patients, ethical implications in patient selection and more.
About Christina Ferraro
Christina Ferraro completed her bachelor of science in nursing at The Ohio State University in 2001 and received a master of science in nursing and certification as a family nurse practitioner from Kent State University in 2016. She joined the Cleveland Clinic in 2003 as...
2023-05-1818 minASTCT TalksTreating Cytopenias After CAR T-cell TherapyIn this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Tania Jain, MBBS. They dive into "How I Treat Cytopenias after CAR T-cell Therapy,” a paper published by Dr. Jain and co-authors (Timothy S. Olson, MD, PhD and Frederick Locke, MD) in Blood in February 2023. They discuss why cytopenias occur after CAR-T therapy, how to evaluate cytopenias after CAR-T therapy, who best to manage cytopenias after CAR-T and more.
About Dr. Rahul Banerjee, MD, FACP
Dr. Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor in the Division of Medical On...
2023-05-0522 min
The PQI PodcastSeason 4 Ep. 15 : Oncology Workforce CollaborativeThis week we sit down with Alison Gulbis, PharmD, BCOP, Kamakshi Rao, PharmD, BCOP, FASHP, and Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA to discuss their work on the Oncology Workforce Collaborative. Alison is a Clinical Pharmacy Manager at the University of Texas MD Anderson Cancer Center in Houston, TX. She obtained her PharmD at the University of Florida and completed her PGY1 and PGY2 residencies at the Medical University of South Carolina. She has been in clinical practice for 19 years at MD Anderson and manages a team of clinical pharmacy specialists in pediatric hematology/oncology and adult s...
2023-04-2725 minASTCT TalksBispecific Antibodies in Myeloma: The Who, What, When, and WhereIn this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Urvi A. Shah, MD, to discuss CAR-T vs bsAbs among academic audiences, bispecific antibodies (in particular commercially available teclistamab), future cycles of teclistamab, infections in published trials of bsAbs in myeloma and more.
About Dr. Rahul Banerjee, MD, FACP
Dr. Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor in the Division of Medical Oncology at the University of Washington and at the Fred Hutchinson Cancer Center. Prior to moving to Seattle, he completed his hematology/oncology fellowship and advanced...
2023-04-1818 minASTCT TalksVirus-Specific T-Cells (VST): Where We Are and How We Got HereIn this latest episode of ASTCT Talks, Dr. Genovefa Papanicolaou, MD sits down with Dr. Richard J. O'Reilly, MD and Professor Karl S. Peggs, MB, BCh, MA, MRCP, FRCPath to discuss Virus-Specific T-Cells (VST). They dive into what VSTs are, safety of VSTs, challenges and opportunities of adoptive cell therapy for viruses and more.
Disclaimer: Dr. Richard O’Reilly received royalties following licensure of the EBV-specific T-cell bank by Atara Biotherapeutics and has subsequently received research support and consultant fees from Atara Biotherapeutics.
About Genovefa Papanicolaou, MD
Genovefa Papanicolaou (@GenPapaMD) is an infectious di...
2023-04-0655 min
Healio MinuteLeukemia Edition: Top Headlines for Week of March 27, 2023In this edition, optimal antibiotics timing among inpatients with cancer; inflammation levels linked to survival in acute myeloid leukemia; dexrazoxane confers long-term cardioprotection for pediatric cancer and more. Read the full coverage here: Optimal antibiotics timing 'likely differs' among inpatients with cancer, neutropenic fever Inflammation levels linked to survival in acute myeloid leukemia Dexrazoxane confers long-term cardioprotection after anthracyclines for pediatric cancer Menin inhibitor produces high response rates in certain acute leukemia subtypes Tisa-cel CAR-T reinfusion lacks durability for younger patients with B-cell ALL References:
2023-03-3014 minHealio MinuteLeukemia Edition: Top Headlines for Week of March 27, 2023In this edition, optimal antibiotics timing among inpatients with cancer; inflammation levels linked to survival in acute myeloid leukemia; dexrazoxane confers long-term cardioprotection for pediatric cancer and more. Read the full coverage here: Optimal antibiotics timing 'likely differs' among inpatients with cancer, neutropenic fever Inflammation levels linked to survival in acute myeloid leukemia Dexrazoxane confers long-term cardioprotection after anthracyclines for pediatric cancer Menin inhibitor produces high response rates in certain acute leukemia subtypes Tisa-cel CAR-T reinfusion lacks durability for younger patients with B-cell ALL References:
2023-03-3014 min
Healio MinuteLeukemia Edition: Top Headlines for Week of March 13, 2023In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more. Read the full coverage here: Outpatient HSCT feasible for older adults with AML, myelodysplastic syndrome Ponatinib 'should be considered a standard of care' for newly diagnosed Ph+ALL Iomab-B may increase transplant access, improve outcomes in relapsed/refractory AML Living along US-Mexico border linked to higher risk for death among children with leukemia Breyanzi study meets complete response endpoint for leukemia...
2023-03-1614 minHealio MinuteLeukemia Edition: Top Headlines for Week of March 13, 2023In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more. Read the full coverage here: Outpatient HSCT feasible for older adults with AML, myelodysplastic syndrome Ponatinib 'should be considered a standard of care' for newly diagnosed Ph+ALL Iomab-B may increase transplant access, improve outcomes in relapsed/refractory AML Living along US-Mexico border linked to higher risk for death among children with leukemia Breyanzi study meets complete response endpoint for leukemia...
2023-03-1614 min
ASTCT TalksTitans of Transplant: Dr. Micah SkeensIn the next installment of ASTCT’s Titans of Transplant series, Dr. Micah Skeens, PhD, MS, CPNP-PC, is interviewed by Darren J. Johnson, PA. They dive into her story and background as a pediatric oncology nurse of over 20 years and current research interests and passions, including development of an app for medical adherence in transplant. They also discuss importance of mentorship in the field for APPs, the value in making a difference in patients’ lives, current inspirations and more.
About Darren J. Johnson
Darren J. Johnson, PA, is a physician assistant who has been working in t...
2023-03-1533 min
Health Professional Radio - PodcastHow Some Bone Marrow/Stem Cell Transplants Can Lead to ComplicationsDr. Corey Cutler, MD, MPH, FRCPC, Medical Director, Stem Cell Transplant Program, Dana-Farber Cancer Institute and Vice President, American Society for Transplantation and Cellular Therapy (ASTCT) and GVHD patient Meredith A. Cowden, MA, AT, LPCC-S, Patient Advocacy Director of the Meredith A. Cowden Foundation discuss graft-versus-host-disease (GVHD), a rare disease that commonly impacts allogeneic (meaning cells that come from a donor) blood and marrow transplant recipients, the inaugural GVHD Day on Feb 17, 2023, the importance of bringing attention to this rare disease, and a new website for the GVHD community to access a variety of educational resources and support tools...
2023-03-0907 minASTCT TalksMRD in Relation to Transplantation and Cell TherapyIn this latest episode of ASTCT Talks, Dr. Andrés Gómez De León sits down with Dr. Aaron Logan to discuss development of current techniques for quantifying measurable residual disease (MRD) in acute lymphoblastic leukemia and MRD's relation to transplantation and cell therapy. They discuss the concept of MRD and its relevance in the treatment of leukemia as a prognostic marker and to help guide clinical decision-making, as well as the future of MRD research and more.
About Dr. Andrés Gómez De León
Dr. Andrés Gómez De León (@GomezDLeo...
2023-02-071h 00ASTCT TalksThe Winter "Tridemic" in Cellular TherapyIn this latest episode of ASTCT Talks, Dr. Firas El Chaer talks with Dr. Alpana Waghmare and Dr. Michael Ison to discuss the winter “Tridemic,” which includes COVID, flu and respiratory syncytial virus (RSV). They discuss the diagnostic and treatment approaches for the Tridemic in recipients of hematopoietic cell transplantation and cellular therapy, examine the precautions and best practices for recipients of hematopoietic cell transplantation and more. This podcast was recorded on December 21, 2022.
About Dr. Firas El Chaer
Firas El Chaer, MD, (@FirasElChaer) is an assistant professor of medicine who specializes in hematology and oncology. He c...
2023-01-1149 minASTCT TalksTitans of Transplant: Susan Slater, MN, FNP-BCIn the next installment of ASTCT’s Titans of Transplant series, Susan Slater, nurse practitioner and recipient of the Best APP Abstract Award at the 2016 BMT Tandem meetings and the 2020 APP SIG Lifetime Achievement Award, is interviewed by Dr. Jennifer Saultz, Assistant Professor of Medicine at Oregon Healthy & Science University and a member of the Adult Transplant and cellular therapy team.
About Susan Slater
Susan Slater, MN, FNP-BC is an Assistant Professor of Medicine in the Knight Cancer Institute at Oregon Health & Science University. She has 25 years’ experience as nurse practitioner caring for patients with hema...
2022-12-0720 minASTCT TalksMonkeypox in HCT and CAR TIn this latest episode of ASTCT Talks, Dr. Steven Pergam talks with Dr. Amy Spallone and Dr. Emily Ford to discuss Monkeypox in HCT and CAR T. They cover the basics of Monkeypox, risk factors for Monkeypox among patients, presenting symptoms for Monkeypox, vaccines for Monkeypox and more.
About Dr. Steven Pergam
Dr. Steven Pergam (@PergamIC) is an Infectious Diseases Physician and Professor at the Fred Hutchinson Cancer Center in the Division of Vaccine and Infectious Diseases. He is also the Infection Prevention Director of the Cancer Center, and a faculty member of the University o...
2022-10-2647 minASTCT TalksTitans of Transplant: Dr. John F. DiPersioIn the next installment of ASTCT’s Titans of Transplant series, Dr. John. F. DiPersio, an internationally recognized leader in hematopoietic stem cell transplantation and acute leukemia and past president of ASTCT (2019) is interviewed by Dr. Roman Shapiro.
About Dr. John F. DiPersio
John F. DiPersio, MD, PhD is deputy director at Alvin J. Siteman Cancer Center, director at Center for Gene and Cellular Immunotherapy and chief of the division of oncology at Washington University School of Medicine in St. Louis and the Virginia E. and Samuel J. Golman professor of medicine. His research focuses on...
2022-10-1040 minASTCT TalksCelebrating Advocacy Efforts, Overcoming Barriers and Addressing Inequity in Cellular TransplantationIn this latest episode of ASTCT Talks, we celebrate National Hispanic Heritage Month as Dr. Jennifer Saultz talks with Dr. Eneida Nemecek to highlight her work and share her advocacy, passion and journey to becoming a medical director of clinical research. She explains her experiences as a Latina woman in the field of cellular therapy and transplantation, barriers Hispanic and marginalized groups face in cellular transplantation, inclusivity efforts for health equity, the value of mentor and sponsorship and more.
About Dr. Jennifer Saultz
Dr. Jennifer Saultz is an Assistant Professor of Medicine at Oregon Healthy...
2022-09-2836 minASTCT TalksTitans of Transplant: Dr. Rainer StorbIn the next installment of ASTCT’s Titans of Transplant series, Dr. Rainer Storb, one of the pioneers who established allogeneic, or donor, blood stem cell transplantation as a cure for diseases like leukemia and aplastic anemia, is interviewed by Dr. Masumi Ueda.
About Dr. Storb
Rainer Storb, MD, serves as Professor and Head of Transplantation Biology Program Clinical Research Division at Fred Hutch.
About Dr. Ueda
Masumi Ueda, MD, serves as Associate Professor in the Clinical Research Division of the Fred Hutchinson Cancer Center and the Division of Medical Oncology at...
2022-09-1342 minASTCT TalksTitans of Transplant: Dr. Adriana SeberIn the next installment of ASTCT’s Titans of Transplant series, Dr. Hema Rangarajan, an oncologist at Nationwide Children’s Hospital and a member of the ASTCT Content Committee, speaks with Dr. Adriana Seber, who is a professor of medicine at the University of Miami and the Kalish Family Chair and Chief of Division of Transplantation and Cellular Therapy at Sylvester Comprehensive Cancer Center and Vice-President of the Brazilian BMT Society.
The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nurses, social workers and more who were on the frontlines of the...
2022-07-1240 min
ASTCT TalksFinding Affordable and Accessible Hematopoietic Cell TransplantsIn this latest episode of ASTCT Talks, Dr. Andrés Gómez De León, a physician at the Universidad Autónoma de Nuevo León Hematology Service in Monterrey, Mexico, and Dr. Cristóbal Frutos, who is the Coordinator for the Bone Marrow transplant Unito the Hospital Central Instituto de Previsión Social in Asunción Paraguay, discuss the current state of transplant activities and the importance of having access to cell therapies worldwide. Dr. Frutos presented on this topic during the 2022 Tandem Meetings of ASTCT & CIBMTR.
2022-06-2953 minASTCT TalksTitans of Transplant: Dr. Krishna KomanduriIn the next installment of ASTCT’s Titans of Transplant series, Dr. Rahul Banerjee, Advanced Fellow, BMT/CAR-T Therapy, with the Division of Hematology/Oncology in the Department of Medicine at the University of California San Francisco, speaks with Dr. Krishna Komanduri, who is a professor of medicine at the University of Miami and the Kalish Family Chair and Chief of Division of Transplantation and Cellular Therapy at Sylvester Comprehensive Cancer Center.
The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nurses, social workers and more who were on the frontlines of...
2022-04-0441 minASTCT TalksManaging COVID-19 in Transplant PatientsIn the latest episode of ASTCT Talks, Dr. Zainab Shahid, internist in the hematology department of the Levine Cancer Institute Morehead in Charlotte, North Carolina, leads a conversation around ongoing clinical challenges regarding management of COVID-19 in transplant cellular therapy recipients. Dr. Shahid is joined by some of the foremost experts in infectious disease and transplant patients:
Dr. Esther Babady is chief of the clinical microbiology service at Memorial Sloan Kettering Cancer Center;
Dr. Mini Kamboj is chief medical epidemiologist for infection control at Memorial Sloan Kettering Cancer Center;
and Dr. Camille Kotton is the Clinical Director, Transplant...
2022-03-1650 minASTCT TalksTitans of Transplant: Dr. Gregorio JaimovichIn the second installment of ASTCT’s Titans of Transplant series, Dr. Andrés Gómez De León, physician with the Universidad Autónoma de Nuevo León Hematology Service in Monterrey, Mexico, speaks with Dr. Gregorio Jaimovich, who is the director of the bone marrow transplantation programs of the Favaloro University Hospital and the Anchorena Hospital in Buenos Aires, Argentina.
The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nurses, social workers and more who were on the frontlines of the early days of transplant.
2022-02-1527 minASTCT TalksTitans of Transplant: Dr. Mary HorowitzIn the first episode of ASTCT’s Titans of Transplant series, Dr. Jennifer Holter-Chakrabarty, physician with The University of Oklahoma Health and professor of medicine in hematology/oncology, speaks with Dr. Mary Horowitz, whose credentials include professor and deputy cancer center director at the Medical College of Wisconsin; the Robert A. Uihlein, Jr. Chair in hematologic research; associate director of genomics; and scientific director emeritus of CIBMTR.
The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nurses, social workers and more who were on the frontlines of the early days of tr...
2022-01-2437 minASTCT TalksA Deep Dive On Early Time-to-TociJoin Dr. Rahul Banerjee, Advanced Fellow of BMT / CAR T Therapy in the Department of Medicine at the University of California San Francisco, and Dr. Nina Shah, Associate Professor in the Department of Medicine at UC San Francisco, as they discuss their paper “Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.” The paper was co-authored by Drs. Shah and Banerjee, along with several colleagues, and was published in ASTCT’s Transplantation and Cellular Therapy Journal in March.
2021-07-2925 minASTCT TalksAdvancements in Immunotherapies with Dr. DiPersioThis episode of ASTCT Talks features a recently recorded conversation with Dr. John DiPersio, a Bone Marrow Transplant Specialist and Medical Oncologist at the Siteman Cancer Center at the Washington University School of Medicine, and a past president of ASTCT. We discuss emerging therapies to treat AML, advancements in immunotherapies, and much more.
2021-06-1028 minASTCT TalksOutpatient Haploidentical Stem Cell TransplantationIn this episode of ASTCT Talks, Dr. Andrés Gómez De León, physician at the Universidad Autónoma de Nuevo León Hematology Service in Monterrey, Mexico, and Dr. Perla Colunga, who is one of the specialist physicians in the hematology service of UANL, discuss their paper “Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible,” which was published in the Transplantation and Cellular Therapy journal in December.
2021-05-2523 minASTCT TalksA Deep Dive on Chronic GVHDIn this episode of ASTCT Talks, we’re joined by Steven Pavletic, MD, MS, Senior Clinician, Immune Deficiency Cellular Therapy Program, National Cancer Institute Center for Cancer Research; and Kirk Schultz, MD, Professor, University of British Columbia BC Children’s Hospital. Our conversation spans all-things chronic GVHD, including the latest research and discussions coming out the Chronic GVHD Consensus Conference, held in November 2020.
2021-03-2435 minASTCT TalksThe Role of MRD in Multiple MyelomaIn this episode of ASTCT Talks, we sit down with Parameswaran Hari, MD, MCRP to discuss the role of minimal residual disease in multiple myeloma. Hari, the Armand J. Quick/William F. Stapp Professor of Hematology and the Chief of the Division of Hematology/Oncology at the Medical College of Wisconsin, said advances in MRD testing signals improvement in progression-free survival in multiple myeloma. While this is good news for clinicians, there’s still a ways to go to ensure MRD testing is being understood correctly.
2020-12-1017 minASTCT TalksMRD Negativity and Lenalidomide Maintenance Therapy: The Possible Next Chapter in Multiple Myeloma CareOn this episode of ASTCT Talks, we sit down with Dilan Patel, MD, advanced BMT fellow at Washington University School of Medicine in St. Louis. Patel was the lead author on a paper that explored minimal residual disease negativity and lenalidomide maintenance therapy, and how those were associated with superior survival outcomes for patients with multiple myeloma.
2020-12-0216 minASTCT TalksDr. Lia Gore Discusses Bispecific T-Cell Engagers in Pediatric ALL ResearchIn this episode of ASTCT Talks, we sit down with Dr. Lia Gore, professor of pediatrics in hematology-oncology and bone marrow transplantation and co-director of the Developmental Therapeutics Program at the University of Colorado Cancer Center. Dr. Gore was the co-investigator on the AALL1331 trial and led the preceding open-label Phase 1–2 trial, AALL1121, which was the first to demonstrate the antileukemic activity of single-agent blinatumomab in children with relapsed or refractory B-ALL. We talk about her research and how the trial signals future research of bispecifics in pediatric care.
2020-11-1226 min
Ligne de MIRLigne de MIR n°59 – Le Professeur Zafrani nous parle des CAR T cellsLe Professeur Lara Zafrani, PU-PH dans le service de Médecine Intensive Réanimation de l’Hôpital Saint-Louis à Paris, nous parle CAR T cells.Aucun lien d’intérêt déclaré.Sommaire :• Qu'est ce que sont Les CAR T cells ?• Quelles sont les complications des CAR T cells que l'on peut voir en réanimation ?• Quelle est la prise en charge de ces complications ?Références : Chimeric antigen receptor T cells for sustained remissions in leukemia.Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A,Gonzalez VE...
2020-06-0108 min